tbuckley/cabot-search huggingface dataset:
AB0534 The Relationship of Pentraxin-3 Levels in Behcet Disease with IL-17, Disease Activity and Atherosclerotic Risk Factors
Authors: S. Sağ, A. Kamanlı, I. Tekeoğlu, K. Nas, M.S. Sağ, H. Harman, M. Altındiş
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several factors have been implicated as contributing to the risk of atherosclerosis in patients with BD. (1) These include inflammatory mediators such as cytokines and adhesion molecules and traditional cardiovascular risk factors such as age, high blood pressure, and dyslipidemia.(2) PTX3 also acts as a modulator of inflammatory processes and is involved in the development of atherosclerotic lesions. It is produced by endothelial cells in atherosclerotic plaques. <h3>Objectives</h3> With this study we aimed to identify the levels of the proteins like Pentraxin and Fetuin-A which are thought to have a role in the progress of atherosclerotic and cardiovascular disorders in Behçet disease and the relationship of these with disease activity, inflammatory cytokine, insulin resistance and dyslipidemia. <h3>Methods</h3> This study included 58 patients (36 female, 22 male) with Behçet disease and 20 healthy controls. Serum pentraxin-3, fetuin-A, IL-17 and insulin concentrations were determined. Also, HOMA-IR values were calculated. Disease activity was assessed with Behcet9s Disease Current Activity Form (BDCAF). <h3>Results</h3> PTX3 and fetuin-A levels were not correlated with ESR, CRP, and any domains of BDCAF scores. IL-17 levels were significantly positively correlated with arthritis of BDCAF scores. there wasn9t any significant relationship between the lipid profile and PTX3, IL17 and fetuin-A levels. There wasn9t any correlation between PTX and IL 17, fetuin-A, insulin, HOMA IR levels (p&gt;0.05). <h3>Conclusions</h3> Just like CRP, PTX3 is an acute-phase reactant and it is considers as an inflammatory and atherosclerotic biomarker. In this study, we presented that PTX3 can increase like IL-17 but there aren9t any relation between the disease activity and coronary risk factors such as serum lipids, glucose intolerance and obesity. Since this is a cross sectional study, to determine higher levels of pentraxin in BD patients who also have higher cardiovascular disease incidences, the patients have to be followed in the longer run. To identify these long-term studies to quantified atherosclerosis are required. <h3>References</h3> Pamuk GE, Pamuk ON, Or€um H, et al. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behcet9s disease? A comparative study. Blood Coagul Fibrinolysis 2010; 21: 113e117. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Behcet9s Syndrome. Semin Arthritis Rheum 2008; 38:1e12. <h3>Disclosure of Interest</h3> None declared
What mediates the effects of thrombospondin-1 in pulmonary hypertension? New evidence for a dual-pronged role of CD47
Authors: Wolfgang M. Kuebler
Journal: Cardiovascular Research (2016)

This editorial refers to ‘TSP1–CD47 signalling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction’ by Natasha M. Rogers et al. pp. 15–29. 

Of late, thrombospondin-1 (TSP1) has emerged as an important new mediator in pulmonary hypertension (PH), a chronic and ultimately fatal disease of the pulmonary circulation that is characterized by increased pulmonary artery pressure (>25 mmHg), and the subsequent development of right ventricular hypertrophy and ultimately, right ventricular failure. Despite the introduction of several lines of pharmacological therapies since the 1980s, 5-year mortality rates remain high,1 stressing a large unmet need for new and better therapeutic targets, and hence, a better in-depth understanding of the cellular mechanisms and signalling cascades that underlie the characteristic pathophysiology of PH. At the cellular level, PH is characterized by a simultaneous imbalance of proliferative, hypertrophic, and apoptotic processes in lung vascular endothelial and smooth muscle cells, resulting in complex and at times seemingly opposing effects that include features of both angiogenesis and vessel pruning, and thickening of the vascular intima and media with smooth muscle cells taking on both synthetic, proliferative and contractile, hypertrophic phenotypes. In addition, inflammatory and auto-immune processes as well as activation of components of the coagulation cascade contribute to the initiation and progression of PH, although their interplay with the cellular processes driving lung vascular remodelling is poorly understood.

TSP1 is a multifunctional protein that is expressed and secreted from various different cell types many of which are directly or indirectly involved in the pathogenesis of PH, such as pulmonary fibroblasts, endothelial, and smooth muscle cells, as well as macrophages and platelets.2 In a recent prospective trial, circulating TSP1 levels were found to be >10 times higher in 93 patients with precapillary PH when compared with 19 control subjects without PH.3 Notably, …
Similar Incidence of Typhlitis in Patients Receiving Various Doses of Daunorubicin or Idarubicin As Induction for Acute Myeloid Leukemia
Authors: Amanda N Seddon, Angela G Michael, Nelly G. Adel, Martin S. Tallman, Oguz Akin, Joshua Chaim, Esther Drill
Journal: Blood (2014)
No Evidence That Protein Noise-Induced Epigenetic Epistasis Constrains Gene Expression Evolution
Authors: Gábor Boross, Balázs Papp
Journal: Molecular Biology and Evolution (2016)

Changes in gene expression can affect phenotypes and therefore both its level and stochastic variability are frequently under selection. It has recently been proposed that epistatic interactions influence gene expression evolution: gene pairs where simultaneous knockout is more deleterious than expected should evolve reduced expression noise to avoid concurrent low expression of both proteins. In apparent support, yeast genes with many epistatic partners have low expression variation both among isogenic individuals and between species. However, the specific predictions and basic assumptions of this verbal model remain untested. Using bioinformatics analysis, we first demonstrate that the model’s predictions are unsupported by available large-scale data. Based on quantitative biochemical modeling, we then show that epistasis between expression reductions (epigenetic epistasis) is not expected to aggravate the fitness cost of stochastic expression, which is in sharp contrast to the verbal argument. This nonintuitive result can be readily explained by the typical diminishing return of fitness on gene activity and by the fact that expression noise not only decreases but also increases the abundance of proteins. Overall, we conclude that stochastic variation in epistatic partners is unlikely to drive noise minimization or constrain gene expression divergence on a genomic scale.
A Randomized Trial Investigating an Exercise Program to Prevent Osteoporosis and Motor Problems during Treatment for Childhood Acute Lymphoblastic Leukemia.
Authors: Mariel L. te Winkel, Annelies Hartman, Robert D. van Beek, Sabine M.P.F. de Muinck Keizer-Schrama, Han C.G. Kemper, Wim C.J. Hop, Marry M. van den Heuvel-Eibrink, Rob Pieters
Journal: Blood (2008)
<i>HER2</i> Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
Authors: Angela N. Bartley, Mary Kay Washington, Carol Colasacco, Christina B. Ventura, Nofisat Ismaila, Al B. Benson, Alfredo Carrato, Margaret L. Gulley, Dhanpat Jain, Sanjay Kakar, Helen J. Mackay, Catherine Streutker, Laura Tang, Megan Troxell, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2017)

Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. Objectives To establish an evidence-based guideline for HER2 testing in patients with GEA, formalize the algorithms for methods to improve the accuracy of HER2 testing while addressing which patients and tumor specimens are appropriate, and to provide guidance on clinical decision making. Design The College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and the American Society of Clinical Oncology (ASCO) convened an Expert Panel to conduct a systematic review of the literature to develop an evidence-based guideline with recommendations for optimal HER2 testing in patients with GEA. Results The Panel is proposing 11 recommendations with strong agreement from the open comment participants. Recommendations The Panel recommends that tumor specimen(s) from all patients with advanced GEA, who are candidates for HER2-targeted therapy, should be assessed for HER2 status before the initiation of HER2-targeted therapy. Clinicians should offer combination chemotherapy and an HER2-targeted agent as initial therapy for all patients with HER2-positive advanced GEA. For pathologists, guidance is provided for morphologic selection of neoplastic tissue, testing algorithms, scoring methods, interpretation and reporting of results, and laboratory quality assurance. Conclusion This guideline provides specific recommendations for assessment of HER2 in patients with advanced GEA while addressing pertinent technical issues and clinical implications of the results.
High Glucose Activates AKT Signaling and Induces Upregulation of Genes Encoding Glycolytic Enzymes Glut-1 and HK-2 in Acute Lymphocytic Leukemia.
Authors: Daniela Buglio, Wendy Schober, Rooha Contractor, Teresa McQueen, Zhihong Zeng, Hagop Kantarjian, Mary A. Weiser, Michael Andreeff, Marina Konopleva
Journal: Blood (2004)
Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study
Authors: Kheira Beldjord, Elizabeth Macintyre, Véronique Lhéritier, Marie-Laure Boulland, Thibaut Leguay, Xavier Thomas, Jean-Michel Cayuela, Nathalie Grardel, Yves Chalandon, Nicolas Boissel, Beat Schäfer, Hélène Cavé, Patrice Chevallier, Agnès Buzyn, Thierry Fest, Vahid Asnafi, Oumedaly Reman, Marie-Christine Béné, Françoise Huguet, Sylvie Chevret, Norbert Ifrah, Hervé Dombret
Journal: Blood (2011)
The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).
Authors: Alissa Huston, Ujjal Singha, Yazan Alsayed, Lanie Francis, Ganwei Lu, Judy Anderson, Suzanne Lentzsch, G. David Roodman, Irene M. Ghobrial
Journal: Blood (2005)
AB0267 No Remarkable Differences on Sonograms of Wrist, Metacarpophalangeal and Proximal Interphalangeal Joints between Rheumatoid Factor Negative Rheumatoid Arthritis and Rheumatoid Factor Positive Rheumatoid Arthritis Patients
Authors: D.F. Lin, Z.Y. Hu, X.H. Guo, J.Y. Cao, Y.F. Pan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> It is reported RF-negative Rheumatoid Arthritis (RF-nRA) had distinct genetic background and pathogenesis mechanism leading to different prognosis and therapy response from RF-positive Rheumatoid Arthritis (RF-pRA). Ultrasound (US) of wrist, metacarpophalangeal (MCP) and proximal interphalangeal joints (PIP) which are the classical zone of RA involvement might verify whether the joint destruction would be different in both group. <h3>Objectives</h3> To verify whether the joint destruction would be different in RF-negative Rheumatoid Arthritis (RF-nRA) and RF-positive Rheumatoid Arthritis (RF-pRA) patients. <h3>Methods</h3> It is a blinded, controlled trial. All cases including RF-nRA group and RF-pRA group satisfied 2009 classification criteria with abnormal swollen or pain in wrists, AMCPs or PIPs. RF-pRA group should have x-ray or MRI evidences The most affected side of joints including the 2nd, 3rd MCPs, Athe 2nd, 3rd PIPs and wrists were examined. US examination and scoring system referred to Backhaus9s US7 scoring system related regions. In addition, synovitis in gray-scale US (GSUS) on dorsal side of the 2nd, 3rd MCPs and PIPs (0–3 grade) and bone erosions on dorso-median, ulnar, palmo-median sides (0 or 1 if absent/present) of wrist in GSUS were also counted in to get a total of 0–106 scores. DAS 28 (3 variables) was employed to divide each of the 2 groups into 4 subgroup to assess the sonograms in different disease activity levels. <h3>Results</h3> 1) 15 RF-nRA cases and 41 RF-pRA cases were enrolled. Mean age (53.8yrs, 57.2yrs), female-male ratio(29:12,16:9), and disease duration(7.53,7.88) of 2 groups were described as above. DAS-28&gt;5.1 subgroups in both 2 groups had the most cases (RF-nRA/RFpRAremission:low:moderate:high=3:2:4:6/1:5:15:20). 2) DAS-28 had highly positive correlation(r=0.95) to US sum scores while poor positive correlation with synovitis GDUS sum scores or synovial Power Doppler(PD) signals sum scores alone.(r=0.57,0.62) 3) No significant differences between RF-nRA and RF-pRA in aspect of synovitis in GDUS, synovial PD signals, and bone erosions in GDUS in wrists, MCPs, PIPs respectively in different levels. <h3>Conclusions</h3> Our study has not found any distinctions in most affected joints between RF-nRA and RF-pRA patients. <h3>Disclosure of Interest</h3> None declared
Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma
Authors: Xenofon Papanikolaou, Adam Rosenthal, Rashid Z Khan, Joshua Epstein, Christoph Heuck, Madhav V. Dhodapkar, Yogesh Jethava, Maurizio Zangari, Omar Atiq, Sarah Waheed, Faith Davies, Gareth J Morgan, Bart Barlogie
Journal: Blood (2014)
OP0285 The Eular Task Force for Standardising Minimum Data Collection in Rheumatoid Arthritis Observational Research: Results of A Hierarchical Literature Review: Table 1.
Authors: K. Chatzidionysiou, E. Nikiphorou, L. Gossec, K. Hyrich, C. Filip, Y. van Eijk-Hustings, P. Williamson, W. Dixon, J. Askling, H. Radner
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is considerable variation in the type of information used in rheumatoid arthritis (RA) observational studies. This, in turn, makes collaborative RA observational research challenging. As part of a larger initiative (EULAR Task Force) a step-wise approach was designed in order to achieve a consensus on a standardized minimum core dataset (MCD) with items (i.e. "what to collect") and instruments (i.e. "how to collect"). <h3>Objectives</h3> To undertake a literature review designed to construct a comprehensive list of items and instruments currently collected across observational RA studies in Europe. This will ultimately inform the development of a MCD for collaborative RA research. <h3>Methods</h3> A hierarchical literature review of published articles that were I) observational cohorts or registers II) including RA patients and III) were initiated in Europe, was performed. Results were compared and cross-checked with EULAR recommendations for data reporting in RA clinical trials and trial extension studies for management of RA, The EULAR outcome measures library (OML) and the results of an initial survey undertaken by our group<sup>1</sup>. The latter was a web-survey involving a smaller sample of RA registers and clinical cohorts. The current literature review expanded to involve all existing RA registers and cohorts in published literature. From the literature, information of what is collected (item) and how (instrument) was extracted and the frequency of data collection was calculated. <h3>Results</h3> Published articles from 67 different European RA registers and cohorts were included. The number of patients recruited in each register ranged from 130 to more than 50,000. A total of 40 different items were identified comprising &gt;100 different instruments Most studies included a measure of disease duration, disease activity, current DMARD use or physical function although the choice of instrument within each item varied widely in many cases (table 1). For example, 8 different composite scores of disease activity are being captured. Relative agreement on specific items did not always, however, entail agreement in terms of instruments. <h3>Conclusions</h3> Information captured in registers is heterogeneous. The frequency of collection of items and instruments informed voting in the first face-to-face meeting, alongside the expert panel survey. <h3>References</h3> Radner H. el al. Consistency and utility of data items across European rheumatoid arthritis clinical cohorts and registers. Arthritis Care Res 2015 <h3>Disclosure of Interest</h3> None declared
Parathyroid Hormones (PTH) Serum Variations Are Associated with Bortezomib Response in Multiple Myeloma Patients
Authors: Maurizio Zangari, Lisa Pappas, Fenghuang Zhan, Naveen Sanath kumar, Federica Cavallo, Larry J Suva, Guido Tricot, Dixie-Lee Esseltine, Shmuel Yaccoby
Journal: Blood (2008)
Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma
Authors: Craig C. Hofmeister, Mindy A Bowers, Anissa Bingman, Gerard Lozanski, Robert A. Baiocchi, William Falk, Don M. Benson, Yvonne A Efebera, Kristina Humphries, Megan Sell, Carli N Greenfield, Mark E Lustberg, John L. Vaughn, Christian Tyler Earl, Susan Geyer, Steven M. Devine
Journal: Blood (2012)
Copy Number Variants Modulation and Their Clinical Impact in Multiple Myeloma
Authors: Zuzana Kufova, Lucie Brozova, Pavel Nemec, Jan Smetana, Elena Kryukova, Jana Filipova, Lenka Sedlarikova, Sabina Sevcikova, Jiri Jarkovsky, Fedor Kryukov, Roman Hajek
Journal: Blood (2015)
Significant Correlation between Immunophenotypings and Cytogenetic Features by Analysis of High Resolution Flow Cytometry with WHO Classification in Adult Acute Myeloid Leukemia in China.
Authors: Xingbing Wang, Jine Zheng, Junxia Yao, Jun Liu, Jin Yang, Yanli He, Jingming Yu, Jun Wei, Zhongping Liu, Hongzhou Zhao, Hongrui Li, Wen Du, Jiahua Zhang, Xiangjun Chen, Wei Liu, Shiang Huang
Journal: Blood (2004)
P1.46: Phase I Study of Nivolumab + Nab-Paclitaxel in Solid Tumors: Preliminary Analysis of the Non-Small Cell Lung Cancer Cohort
Authors: Ben George, Karen Kelly, Amy Ko, Hatem Soliman, Nataliya Trunova, Zev Wainberg, David Waterhouse, Peter O'Dwyer
Journal: Journal of Thoracic Oncology (2016)
Analysis of Outcome of Patients with Acute Myeloid Leukemia According to Socio-Economic Status
Authors: Namali Pierson, Shawn Chaudry, Gabriel Vidal, Michael Machiorlatti, Summer Frank, Sara K. Vesely, James K. Feisal, Samer A Srour, Mohammad O. Khalil, Alexandra Ikeguchi, Mohamad Khawandanah, Mohamad Cherry
Journal: Blood (2015)
Whole Brain Radiation Alone Brings the Favorable Outcomes for AIDS Related Primary Central Nervous System Lymphoma (PCNSL) Especially with Good Performance Status in the HAART Era.
Authors: Hirokazu Nagai, Takashi Odawara, Atsushi Ajisawa, Shotaro Hagiwara, Tomoko Uehira, Hideki Uchiumi, Mihoko Yotsumoto, Toshikazu Miyakawa, Akira Watanabe, Mitsuru Konishi, Seiji Saito, Souichirou Takahama, Masao Tateyama, Seiji Okada
Journal: Blood (2009)
AB0694 Inertial Sensor for The Assessment of Cervical Range of Movement in Axial Spondyloarthritis
Authors: J.L. Garrido-Castro, C. Gonzalez-Navas, J. Castro-Jurado, P. Font-Ugalde, E. Collantes-Estevez
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Axial Spondyloarthritis (AxSpA) affects mainly the spine reducing patient mobility including neck. Several tools have been used to evaluate range of motion in AxSpA, but these tools have problems of reliability and accuracy. Motion capture [1], has been recently developed and validated, however a dedicated laboratory of movement is needed. IMU sensors (Inertial Measurement Unit) are a new and cheap kind of technology that allows knowing 3D orientation. These sensors could provide equivalent results to motion capture, with lower requirements, although validation processes are needed. <h3>Objectives</h3> To evaluate reliability of an inertial sensor IMU to assess cervical range of movement in patients with AxSpA. <h3>Methods</h3> 7 male patients with AxSpA (age 55.9±11.9, time of evolution 14.37±10.74) were included. An IMU sensor (Shimmer3<sup>©</sup>) placed on the patient9s forehead was used. 4 reflective markers were attached to the head using a band (one above the sensor, two over the tragus, and one in the occiput). To detect movement of the trunk, 4 more markers were used (2 over the shoulders, 10 cm below C7 and average distance between L4 and C7). 3D reconstruction was performed using the UCOTrack<sup>©</sup> system [1]. 3D orientation was obtained by the sensor and by the UCOTrack, both at 50 Hz. Patient made three bend movements (frontal, lateral and rotation). Measurements were repeated 5 minutes after. PRO questionnaires and structural damage (mSASSS) were also evaluated. Several statistical tests were performed to assess reliability of the sensor and its comparison with the Gold Standard. <h3>Results</h3> Affectation level was widely spread among the study participants (BASDAI: 3.4±2.9; BASFI 4.2±3.9; BASMI 5.3±2.2; UCOASMI: 6.1±2.5; mSASSS: 39.9±22.4; cervical mSASSS: 17.9±8.8). Table shows the measurements in the three ranges of cervical motion and statistical parameters analyzed. <h3>Conclusions</h3> Test/retest values were very similar, with excellent ICCs and low errors. Motion capture system detected some variations from 3° to 13° at the trunk. To place another IMU sensor at C7 to compensate it is recommended. Number of patients were very small and a model that analyzes the entire spine, not only the cervical part, must be developed. This pilot study shows that IMU sensor could be used, with results very similar to gold standard and with good reliability, improving metrology for AxSpA patients. <h3>References</h3> Garrido-Castro JL, Medina-Carnicer R, Schiottis R, Galisteo AM, Collantes-Estevez E, Gonzalez-Navas C. Assessment of spinal mobility in ankylosing spondylitis using a video-based motion capture system. Man Ther. 2012 Oct;17(5):422–6. <h3>Disclosure of Interest</h3> None declared
Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model
Authors: Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Nathan Mathewson, Cynthia Zajac, Chen Liu, Stuart Brabbs, Bailey Redman, Hiroya Tamaki, Julia Wu, Yaping Sun, Pang Zheng, Yang Liu, Pavan Reddy
Journal: Blood (2015)